Incyte Corp (INCY)

102.02
NASDAQ : Health Care
Prev Close 99.93
Day Low/High 98.49 / 104.23
52 Wk Low/High 55.00 / 118.49
Avg Volume 1.45M
Exchange NASDAQ
Shares Outstanding 188.39M
Market Cap 18.83B
P/E Ratio 126.49
Div & Yield N.A. (N.A)

Latest News

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle

The most recent short interest data has been released for the 10/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting

More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting

Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts including data from its ongoing clinical development program for Jakafi ® (ruxolitinib) and its small molecule development programs targeting...

Why Incyte's Shares Could Soon Hit $100

Why Incyte's Shares Could Soon Hit $100

The drug company reported strong earnings.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at 11:30 am (EST) in New York.

Incyte Reports 2016 Third-Quarter Financial Results And Updates Key Clinical Programs

Incyte Reports 2016 Third-Quarter Financial Results And Updates Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2016 third-quarter financial results, including strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

There's Still Time to Buy These 5 Breakout Trades

There's Still Time to Buy These 5 Breakout Trades

November is historically a great month for stock market performance -- here's how you can stack the deck in your favor.

Incyte To Report Third Quarter Financial Results

Incyte To Report Third Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2016 financial results conference call and webcast for 10:00 a.

Additional Phase 1 Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda® (pembrolizumab)

Additional Phase 1 Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) today announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination...

Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab)

Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab)

Incyte Corporation (Nasdaq: INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating...

The New #42 Most Shorted Nasdaq 100 Component: Incyte

The New #42 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 09/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis

NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis

Incyte Corporation (Nasdaq: INCY) today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi ® (ruxolitinib), has been included as a recommended treatment in the latest National Comprehensive Cancer...

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Incyte Supports Those Affected By Rare Blood Cancers On MPN Awareness Day And Throughout Blood Cancer Awareness Month

Incyte Supports Those Affected By Rare Blood Cancers On MPN Awareness Day And Throughout Blood Cancer Awareness Month

Incyte Corporation calls for increased awareness and support for those living with myeloproliferative neoplasms (MPNs) today, MPN Awareness Day, and throughout September, Blood Cancer Awareness Month.

'Mad Money' Lightning Round: I'm Staying With Potash

'Mad Money' Lightning Round: I'm Staying With Potash

Cramer says he liked Yelp's quarter and is staying away from Cheniere Energy.

Jim Cramer's 'Mad Money' Recap: Oil Regains Control of the Stock Market

Jim Cramer's 'Mad Money' Recap: Oil Regains Control of the Stock Market

Cramer finds the good and the bad in the continued oil glut.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Morgan Stanley Global Healthcare Conference on Wednesday, September...

Forbes Magazine Names Incyte To Its List Of World's Most Innovative Companies For Second Consecutive Year

Forbes Magazine Names Incyte To Its List Of World's Most Innovative Companies For Second Consecutive Year

Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4th on Forbes magazine's 2016 list of the World's Most Innovative Companies.

Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal

Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal

Pfizer (PFE) has agreed to acquire Medivation (MDVN) for $14 billion, fueling speculation of a future deal with Incyte (INCY).

How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?

How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?

Barclays increased its price target to $100 on Incyte (INCY) stock this morning.

Why There Is Upside for Incyte Despite Recent Selloff

Why There Is Upside for Incyte Despite Recent Selloff

The company's share price despite reporting better-than-expected earnings and revenue and

Today's Roof Leaker Stock Is Incyte (INCY)

Today's Roof Leaker Stock Is Incyte (INCY)

Trade-Ideas LLC identified Incyte (INCY) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate

Incyte Reports 2016 Second-Quarter Financial Results And Updates Key Clinical Programs

Incyte Reports 2016 Second-Quarter Financial Results And Updates Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2016 second-quarter financial results, including strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders

Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders

Stocks with insider trader activity include CFFI, KERX and INCY

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.